Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906.
Blood Adv. 2023.
PMID: 37327122
Free PMC article.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L.
Sloan SL, et al. Among authors: hinterschied c.
Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419.
Blood. 2023.
PMID: 37267517
Item in Clipboard
Cite
Cite